(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $7.22
发出时间: 15 Feb 2024 @ 04:45
回报率: 20.86%
上一信号: Feb 14 - 03:34
上一信号:
回报率: 12.56 %
Live Chart Being Loaded With Signals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
Stats | |
---|---|
今日成交量 | 1.59M |
平均成交量 | 2.01M |
市值 | 1.92B |
EPS | $0 ( 2024-03-21 ) |
下一个收益日期 | ( $-0.300 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.97 |
ATR14 | $0.0180 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Bishop Hans Edgar | Buy | 2 774 | Common Stock |
2024-04-01 | Fmr Llc | Buy | 0 | Common Stock |
2024-03-08 | Yang Patrick Y | Sell | 25 000 | Common Stock |
2024-03-07 | Williams Douglas E | Buy | 301 875 | Stock Option (Right to Buy) |
2024-03-07 | Williams Douglas E | Buy | 67 083 | Restricted Stock Units |
INSIDER POWER |
---|
6.22 |
Last 97 transactions |
Buy: 15 455 910 | Sell: 11 982 863 |
音量 相关性
Sana Biotechnology, Inc. 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sana Biotechnology, Inc. 相关性 - 货币/商品
Sana Biotechnology, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-30.87M (0.00 %) |
EPS: | $-1.460 |
FY | 2023 |
营收: | $0 |
毛利润: | $-30.87M (0.00 %) |
EPS: | $-1.460 |
FY | 2022 |
营收: | $0 |
毛利润: | $-27.73M (0.00 %) |
EPS: | $-1.410 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.958 |
Financial Reports:
No articles found.
Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。